The antibiotic myxopyronin (Myx) functions by inhibiting bacterial RNA polymerase (RNAP). The binding site on RNAP for Myx-the RNAP "switch region SW1/SW2 subregion"-is different from the binding site on RNAP for the RNAP inhibitor currently used in broad-spectrum antibacterial therapy, rifampin (Rif). Here, we report the frequency, spectrum, and fitness costs of Myx resistance in Staphylococcus aureus. The resistance rate for Myx is 4 ؋ 10 ؊8 to 7 ؋ 10 ؊8 per generation, which is equal within error to the resistance rate for Rif (3 ؋ 10 ؊8 to 10 ؋ 10 ؊8 per generation). Substitutions conferring Myx resistance were obtained in the RNAP ␤ subunit [six substitutions: V1080(1275)I, V1080(1275)L, E1084(1279)K, D1101(1296)E, S1127(1322)L, and S1127 (1322) Mf50 (18, 20, 23, 49) . Myx exhibits broad-spectrum antibacterial activity, with potent antibacterial activity against most Gram-positive species and some Gram-negative species. Myx is under investigation as a potential lead compound for broad-spectrum antibacterial therapy.
M yxopyronin (Myx) is an ␣-pyrone antibiotic produced by
Myxococcus fulvus Mf50 (18, 20, 23, 49) . Myx exhibits broad-spectrum antibacterial activity, with potent antibacterial activity against most Gram-positive species and some Gram-negative species. Myx is under investigation as a potential lead compound for broad-spectrum antibacterial therapy.
Myx functions by inhibiting bacterial RNA polymerase (RNAP) (3, 18, 20, 32, 49) . The binding site on RNAP for Myx is located in the RNAP "switch region" and comprises the RNAP switch region structural elements termed "switch 1" and "switch 2," (switch region SW1/SW2 subregion) (3, 18, 32, 49) . The binding site on RNAP for Myx is different from the binding site on RNAP for the RNAP inhibitor in current use in broad-spectrum antibacterial therapy, rifampin (Rif) (3, 18, 32, 49) . Accordingly, Myx exhibits no cross-resistance with Rif (18, 19, 32, 33, 49) .
Previous studies have provided information about spontaneous resistance frequencies and resistance spectra for Myx (31, 32) . However, the fitness costs of resistance have not previously been assessed.
In this work, we comprehensively evaluate the resistance properties of Myx in Staphylococcus aureus. We report (i) the spontaneous resistance rate for Myx in S. aureus, (ii) the spontaneous resistance spectrum of Myx in S. aureus, and (iii) the fitness costs of substitutions that confer Myx resistance.
MATERIALS AND METHODS

Materials.
(Ϯ)-Myx B was synthesized as described in Hu et al. (19) . Rif was purchased from Sigma, Inc. Bacterial strains were obtained from the American Type Culture Collection.
MICs. Minimal inhibitory concentrations (MICs) in column 2 of Table 1 were quantified using broth microdilution assays (8) . MICs in column 3 of Table 1, and in Tables 3 and 4 , were quantified using spiral gradient endpoint assays, essentially as described previously (38, 45, 54) . Spiral gradient endpoint assays employed 150-mm by 4-mm exponentialgradient plates containing Mueller-Hinton II cation-adjusted agar and 0.5 to 100 g/ml of Myx, 0.0008 to 0.2 g/ml of Rif, or 0.2 to 40 g/ml of Rif. Plates were prepared using an Autoplate 4000 spiral plater (Spiral Biotech, Inc.). Cells were grown to early log phase, adjusted to 1 ϫ 10 8 CFU/ml, and swabbed radially onto plates. Plates were incubated for 16 h at 37°C. For each culture, the streak length was measured using a clear plastic template (Spiral Biotech, Inc.), the test compound concentration at the streak endpoint was calculated using the program SGE (Spiral Biotech, Inc.), and the MIC was defined as the calculated test compound concentration at the streak endpoint.
MBCs. Minimal bactericidal concentrations (MBCs) were determined as follows. Cells (5 ϫ 10 5 CFU/ml, diluted from log-phase cultures) were incubated for 16 h at 37°C in 100 l of Mueller-Hinton II cation-adjusted broth containing amounts of test compound equivalent to 0ϫ MIC, 0.5ϫ MIC, 1ϫ MIC, 2ϫ MIC, or 4ϫ MIC. Samples were diluted 1:1,000; aliquots were applied to Mueller-Hinton II cation-adjusted agar plates, plates were incubated for 16 h at 37°C, and colonies were counted. The MBC was defined as the lowest concentration of test compound that resulted in a Ն99.9% reduction in colony count.
Spontaneous resistance rates. Resistance rates were determined using fluctuation assays (14, 24, 26, 57) . Defined numbers of cells of S. aureus ATCC 12600 (1 ϫ 10 9 CFU/plate) were plated on Mueller-Hinton II cation-adjusted agar containing amounts of test compound equivalent to 1ϫ MIC, 2ϫ MIC, 4ϫ MIC, 8ϫ MIC, or 16ϫ MIC, and numbers of colonies were counted after 24 h at 37°C (at least five independent deter-minations for each concentration of each test compound). Resistance rates and 95% confidence intervals were calculated using the Ma-SandriSarkar maximum-likelihood estimator (MSS-MLE) (27, 44, 50) as implemented on the Fluctuation Analysis Calculator (FALCOR [http://www .keshavsingh.org/protocols/FALCOR.html]) (16) . Sampling correction was performed as described previously (22, 51) .
Sequencing of resistant mutants. Cells were lysed using 1 mg/ml lysozyme and 1 mg/ml lysostaphin (Sigma, Inc.). Genomic DNA was isolated using the Wizard Genomic DNA Purification Kit (Promega, Inc.) according to the procedures specified by the manufacturer, and genomic DNA was quantified by measurement of UV absorbance. The rpoB gene and the rpoC gene were PCR amplified in reaction mixtures containing 0.2 g of genomic DNA, 0.4 M forward and reverse oligonucleotide primers (5=-CGTTAAATAGATAAGTTAATTAAGAATAAATATAGAATCG-3= and 5=-TGGCTTAAAGTACTAAACTGAATCATC-3= for rpoB; 5=-GCC ATTTTAAATAAATGCAAATCAATCAAATAGC-3= and 5=-CCTTTAA TATATTAACATTGAACAAGAGAATTCG-3= for rpoC), 5 U of Taq DNA polymerase (Genscript, Inc.), and 800 M deoxynucleoside triphosphate (dNTP) mix (200 M each dNTP; Agilent, Inc.). The PCR program consisted of an initial denaturation step of 5 min at 94°C, followed by 30 cycles of 30 s at 94°C, 45 s at 48°C, and 4 min at 72°C, with a final extension step of 10 min at 72°C. PCR products containing the rpoB gene (3.5 kb) or the rpoC gene (3.6 kb) were isolated by electrophoresis on 0.8% agarose, extracted from gel slices using a Gel/PCR DNA Fragments Extraction Kit (IBI Scientific, Inc.) according to the procedures specified by the manufacturer, and sequenced (Sanger sequencing; eight sequencing primers per gene).
Resistance fitness costs. Resistance fitness costs were quantified using pairwise-competition fitness assays, essentially as described previously (25, 55) . Equal numbers of log-phase cells of an antibacterial-compoundresistant mutant and the isogenic wild-type parent (ϳ1 ϫ 10 3 CFU each) were mixed in 5 ml of Mueller-Hinton II cation-adjusted broth, and the mixed culture was incubated for 20 h (ϳ20 to ϳ23 doubling times for the isogenic wild-type parent) at 37°C with shaking. At time zero and again at 20 h, the numbers of cells of the antibacterial-compound-resistant mutant and the isogenic wild-type parent were quantified by plating, in parallel, on Mueller-Hinton II cation-adjusted agar containing the antibacterial compound (6.25 g/ml Myx or 0.012 g/ml Rif) and on Mueller-Hinton II cation-adjusted agar without the antibacterial compound, followed by incubation for 20 to 40 h at 37°C and colony counting. Numbers of cells of the antibacterial-compound-resistant mutant were determined from the colony counts on plates containing the antibacterial compound. Numbers of cells of the isogenic wild-type parent were determined by subtracting the colony counts on plates containing the antibacterial compound from the colony counts on plates lacking the antibacterial compound.
The numbers of generations of the resistant mutant (G mut ) and of the wild-type parent (G wt ) were calculated according to Wichelhaus et al. (55) :
(1)
where A mut and A wt are the numbers of CFU/ml for the mutant and wild-type, respectively, at time zero, and B wt and B mut are the numbers of CFU/ml for the mutant and wild-type, respectively, at 20 h. The fitness cost (FC) was calculated according to Sander et al. (42):
Pairwise-competition fitness assays directly comparing Myx-resistant mutants and Rif-resistant mutants were performed in an analogous manner, mixing equal numbers of log-phase cells of a Myx-resistant mutant and an Rif-resistant mutant (ϳ1 ϫ 10 3 CFU each) and quantifying numbers of cells of the Myx-resistant mutant and the Rif-resistant mutant by plating on Mueller-Hinton II cation-adjusted agar containing 6.25 g/ml Myx and on Mueller-Hinton II cation-adjusted agar containing 0.012 g/ml Rif, respectively.
RESULTS
Antibacterial activity of Myx in S. aureus MSSA and S. aureus MRSA. To assess antibacterial activity, we performed MIC assays and minimal bactericidal concentration (MBC) assays. Results are presented in Table 1 . The results indicate, consistent with previous reports (19, 20, 31, 33, 49) , that Myx exhibits potent antibacterial activity against both methicillin-sensitive S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA) (MICs of 0.78 to 1.56 g/ ml). Results of spiral gradient endpoint MIC assays are identical, within one 2-fold serial dilution interval, to results of broth microdilution MIC assays. The results further indicate that Myx is bactericidal against both MSSA and MRSA at concentrations approximately 2ϫ to 3ϫ MIC (MBC of 3.13 to 6.25 g/ml).
Myx resistance in S. aureus: resistance rate. To assess the spontaneous resistance rate for Myx, we performed fluctuation assays (14, 24, 26, 57) , plating defined numbers of cells (ϳ10 9 CFU/plate) of S. aureus ATCC 12600 on agar containing 1ϫ, 2ϫ, 4ϫ, 8ϫ, or 16ϫ MIC of Myx, counting numbers of resistant colonies after 24 h of incubation at 37°C, and calculating resistance rates using the MSS-MLE method (16, 22, 27, 44, 50, 51) . For comparison, we assayed the resistance rate for Rif under the identical experimental conditions. The results are presented in Table 2 . The observed resistance rates for Myx at 1ϫ, 2ϫ, 4ϫ, 8ϫ, and 16ϫ MIC were 7 ϫ 10 Ϫ8 , 7 ϫ 10 Ϫ8 , 6 ϫ 10 Ϫ8 , 4 ϫ 10 Ϫ8 , and 4 ϫ 10 Ϫ8 per generation, respectively. The observed resistance rates for Rif at 1ϫ, 2ϫ, 4ϫ, 8ϫ and 16ϫ MIC were 10 ϫ 10 Ϫ8 , 6 ϫ 10 Ϫ8 , 6 ϫ 10 Ϫ8 , 3 ϫ 10 Ϫ8 , and 3 ϫ 10 Ϫ8 , respectively, per generation, consistent with previously reported values for Rif (30, 34) . Within experimental error, the observed resistance rates for Myx and Rif were identical. We conclude, consistent with previous work (31) , that the resistance rates for Myx and Rif are equal or comparable.
Myx resistance in S. aureus: resistance spectrum. To define the resistance spectrum for Myx, we isolated and sequenced the rpoB and rpoC genes, encoding the RNAP ␤ and ␤= subunits, from each of 17 independent spontaneous Myx-resistant mutants identified in the experiments described in the preceding section. For comparison, to define the resistance spectrum for Rif under identical experimental conditions, we isolated and sequenced the rpoB gene from each of 24 independent spontaneous Rif-resistant mutants identified in the experiments described in the preceding section.
The results for Myx resistance are presented in Table 3 and Fig.  1B . All Myx-resistant mutants were found to contain mutations in (Fig. 1A and B) . None overlapped the binding site on RNAP for Rif (Fig. 1C) or the resistance spectrum on RNAP for Rif (Fig. 1D ). Resistance and cross-resistance levels were quantified using spiral gradient endpoint assays (38, 45, 54) . Six substitutions resulted in 20-fold resistance to Myx, and five substitutions resulted in Ͼ100-fold resistance to Myx (Table 3) . (Compound availability precluded assays at Ͼ100ϫ MIC.) The median resistance level was 20-fold. Consistent with the absence of overlap with the binding site for Rif, no Myx-resistant substitution conferred cross-resistance to Rif ( Table 3) . The results for Rif are presented in Table 4 and Fig. 1D . All Rif-resistant mutants contained mutations in rpoB, consistent with previous reports for Rif resistance in S. aureus and in other bacterial species ( . One Rif-resistant substitution resulted in 60-fold resistance, two resulted in 100-fold resistance, one resulted in 300-fold resistance, and all others resulted in Ն2,000-fold resistance ( Table 4) . The median resistance level was 2,000-fold. Consistent with the absence of overlap with the binding site for Myx (Fig. 1) , no Rif-resistant substitution conferred crossresistance to Myx (Table 4) .
We conclude that the Myx resistance spectrum in S. aureus comprises substitutions of residues of the Myx binding site located in the SW1/SW2 subregion of the RNAP switch region and that the Myx resistance spectrum does not overlap the Rif resistance spectrum (Tables 3 and 4 ; Fig. 1 ). We conclude further that Myx-resistant mutants exhibit generally lower resistance levels than Rif-resistant mutants (with at least 6 of the 11 Myx-resistant mutants exhibiting resistance levels lower than any of the 9 Rif-resistant mutants and with a multiple-orderof-magnitude difference in median resistance levels: i.e., 20-fold versus 2,000-fold).
Myx resistance in S. aureus: resistance fitness costs. To assess the fitness cost of Myx-resistant mutants, we performed pairwisecompetition fitness assays, essentially as described by Lenski and by Wichelhaus et al. (25, 55) . For each identified Myx-resistant mutant, we mixed equal numbers of cells of the Myx-resistant mutant and the isogenic wild-type parent (1 ϫ 10 3 CFU of each), incubated the mixed culture for 20 h at 37°C (20 to 23 doubling times for the wild-type parent), quantified Myx-resistant and wild-type cells by plating cultures in parallel to medium with Myx and without Myx, and calculated the fitness cost per generation (see Materials and Methods). For comparison, we assessed the fitness cost, under identical experimental conditions, for each identified Rif-resistant mutant.
The results for Myx-resistant mutants are presented in Table 3 . All Myx-resistant mutants exhibited nonzero, Ͼ0% per generation, fitness costs. The lowest and highest fitness costs were 4% per generation and 15% per generation, respectively. The mean and median fitness costs were 9% per generation and 8% per generation, respectively. Growth rates of three mutants with substitutions of the RNAP switch region previously have been assessed (28) , but the data in the present study provide the first quantitative measurements of fitness costs of any mutant with substitutions of the RNAP switch region.
The results for Rif are presented in Table 4 , column 5. Three Rif-resistant mutants have fitness costs of zero or less than zero: D471(516)G, D471(516)Y, and H481(526)N (Table 4, boldface). The observed fitness costs for Rif-resistant mutants in S. aureus are in agreement with previously reported data (55). The conclusion that a subset of Rif-resistant mutants exhibit fitness costs of zero or less than zero is in agreement with previous work for multiple bacterial species, including S. aureus (55), Enterococcus faecium (11), Mycobacterium tuberculosis (4, 15) , and E. coli (41) .
To assess the significance of the observed difference in fitness costs of Myx-resistant mutants and Rif-resistant mutants, we performed direct pairwise-competition fitness assays between the two lowest-fitness-cost Myx-resistant mutants [␤ S1127(1322)P and ␤= T925(917)R; fitness costs of 4% per generation and 5% per generation, respectively] and a zero-fitness cost Rif-resistant mutant [␤ H481(526)N]. The results are presented in Table 5 . The results confirm that the two lowest-fitness-cost Myx-resistant mutants are significantly less fit than the zero-fitness-cost Rifresistant mutant. The observed relative fitness costs are equal within error to the predicted relative fitness costs calculated as the difference between the fitness costs of the Myx-resistant mutants (Table 4) . Atomic coordinates for RNAP and Myx are from a crystal structure of the Thermus thermophilus RNAP-Myx complex (32) (Protein Data Bank [PDB] accession code 3DXJ; subunit and ␤= subunit nonconserved regions omitted for clarity). Atomic coordinates for Rif are from the crystal structure of the Thermus aquaticus RNAP-Rif complex (6) (PDB accession code 1I6V). The RNAP active-center Mg 2ϩ is shown as a violet sphere for reference. (Table 6 ).
DISCUSSION
Our results show that Myx has bactericidal activity in S. aureus (Table 1) and define the resistance properties of Myx in S. aureus (Tables 2 to 4 ; Fig. 1 ). Our results indicate that the spontaneous resistance rate for Myx is equal or comparable to that for Rif (Table 2), that the resistance spectrum for Myx does not overlap the resistance spectrum for Rif (Tables 3 and 4 ; Fig. 1B and D) , that the resistance levels of Myx-resistant mutants generally are lower than those of Rif-resistant mutants (Tables 3 and 4 ), and that the resistance fitness costs of all Myx-resistant mutants-but not all Rifresistant mutants-are greater than zero (Tables 3 and 4) .
The finding that the resistance levels of Myx-resistant mutants generally are lower than those of Rif-resistant mutants, together with the finding that fitness costs of all Myx-resistant mutantsbut not all Rif-resistant mutants-are greater than zero, supports the viability of Myx as a lead compound for antibacterial drug development.
The finding that all Myx-resistant mutants, but not all Rifresistant mutants, have significant nonzero fitness costs is particularly noteworthy. Previous work has established a strong correlation between the fitness cost of antibacterial-agent-resistant mutants and the clinical prevalence of antibacterial-agent-resistant mutants (1, 4, 5, 9, 10, 15, 35, 42, 55) . For Rif, this correlation is especially strong (4, 10, 15, 35, 55) . Rif-resistant substitutions that have zero or subzero fitness costs are highly significantly overrepresented in Rif-resistant clinical isolates across multiple bacterial species (4, 10, 15, 35, 55 (40, 43) .
The difference in fitness costs of Myx resistance and Rif resistance presumably relates to the fact that the binding site on RNAP for Myx (the RNAP switch region SW1/SW2 subregion) performs critical functions in opening and closing the RNAP active-center cleft and in DNA binding (3, 18, 32, 39, 49) , whereas the binding site on RNAP for Rif performs no critical functions (18) . Accordingly, substitutions in the SW1/SW2 subregion of the RNAP switch region presumably are more likely to impair RNAP function and thereby to impair viability. Since the nonzero fitness costs are likely to be a property of the switch region SW1/SW2 subregion, it is likely that nonzero fitness costs will be observed not only with Myx but also with other RNAP inhibitors that function through the switch region SW1/SW2 subregion, including corallopyronin and ripostatin (32, 49) . (Table 3 ) minus the fitness cost of the Rif-resistant mutant (Table 4) . c Observed relative fitness costs are from pairwise-competition fitness assays directly comparing the Myx-resistant mutant and the Rif-resistant mutant. 
